Clinical utility of the Liver Frailty Index for predicting muscle atrophy in chronic liver disease patients with hepatocellular carcinoma

Keisuke Hirota(Kurume University Hospital), Takuji Torimura(Omuta hospital), Hiroo Matsuse(Kurume University), Manabu Tomita, Naoto Shiba(Kurume University), Shunji Koya(Kurume University Hospital), Ayu Nagamatsu(Kurume University Hospital), Ryuki Hashida(Kurume University), Takashi Niizeki(Kurume University), Takumi Kawaguchi(Kurume University), Dan Nakano(Kurume University)
Hepatology Research
November 13, 2019
10.1111/hepr.13453
Cited by 38

Related Papers

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
|Gut|2019|732
Therapeutic effects of restricted diet and exercise in obese patients with fatty liver
|Journal of Hepatology|1997|614
Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH‐HCC guidelines) 2019 update
|Hepatology Research|2019|539
Hepatitis C Virus Down-Regulates Insulin Receptor Substrates 1 and 2 through Up-Regulation of Suppressor of Cytokine Signaling 3
|American Journal Of Pathology|2004|536
Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review
|Journal of Hepatology|2016|504